February 29th 2008 | Alternative/buyer beware/natural, Psoriasis Research | 0 Comments
Indian food is delicious, but a highly touted spice in this food largely failed in a small trial designed to test its value in treating psoriasis.
Researchers at the University of Pennsylvania School of Medicine found that despite strong scientific evidence in the laboratory demonstrating the ability of curcumin (the active ingredient in the spice turmeric)
READ THE FULL POST
February 22nd 2008 | Health care system, Public policy issues | 0 Comments
A study of psoriasis treatment in hospital dermatology departments in the United Kingdom has found that “the average waiting time for routine appointments is only 10 weeks….”
It’s unclear how “routine” is defined, but ten weeks would be a terribly long time if you were in the midst of a psoriasis flare.
How does that wait compare
READ THE FULL POST
February 17th 2008 | Patient Stories | 0 Comments
If you have not yet seen it, be sure to check out the February expanded profile of Tony and Jim, who appear in our 2008 Psoriasis Patient Calendar. Biologic therapy, has, in his words, “saved his life.” It’s certainly helped him spend better time with his son.
In retrospect, we should have saved these
READ THE FULL POST
February 11th 2008 | Psoriasis Research, Public policy issues | 0 Comments
Psoriasis Cure Now today applauded Congress and the National Institutes of Health (NIH) for delivering a record $10 million in psoriasis research funding during fiscal year 2007. Psoriasis research has traditionally been underfunded at NIH. Since 1995, NIH funding on other diseases has risen 159% (before inflation), but psoriasis and psoriatic arthritis research
READ THE FULL POST
February 8th 2008 | Uncategorized | 0 Comments
One-year data on ustekinumab (CNTO 1275), Centocor’s experimental psoriasis treatment, were reported last week at a dermatology conference and showed that the treatment sustained its effectiveness and safety for 52 weeks. (Ustekinumab’s 12-week data was reported here.)
In addition, a scientific poster at the conference reported 76 week data consistent with earlier reports. Specifically,
READ THE FULL POST
February 7th 2008 | Uncategorized | 0 Comments
Results from a Phase Two study of apremilast (CC-10004) in psoriasis patients showed promise in terms of both safety and effectiveness at 12 weeks.
When treated with a 20 mg dose of the drug, taken orally twice a day, 24% of patients in the study achieved a 75% improvement in psoriasis symptoms, compared with 10% receiving
READ THE FULL POST
